Inactivation of the
transforming growth factor-beta (
TGF-beta) pathway occurs often in
malignancies of the gastrointestinal (GI) system. However, only a fraction of sporadic GI
tumors exhibit inactivating mutations in early stages of
cancer formation, suggesting that other mechanisms play a critical role in the inactivation of this pathway. Here, we show a wide range of GI
tumors, including those of the stomach, liver and colon in elf+/- and elf+/- / Smad4+/- mutant mice. We found that embryonic liver
fodrin (ELF), a
beta-Spectrin originally identified in endodermal stem/progenitor cells committed to foregut lineage, possesses potent antioncogenic activity and is frequently inactivated in GI
cancers. Specifically,
E-cadherin accumulation at cell-cell contacts and
E-cadherin-
beta-catenin-dependent epithelial cell-cell adhesion is disrupted in elf+/- / Smad4+/- mutant gastric epithelial cells, and could be rescued by ectopic expression of full-length elf, but not Smad3 or Smad4. Subcellular fractionation revealed that
E-cadherin is expressed mainly at the cell membrane after
TGF-beta stimulation. In contrast, elf+/- / Smad4+/- mutant tissues showed abnormal distribution of
E-cadherin that could be rescued by overexpression of ELF but not Smad3 or Smad4. Our results identify a group of common lethal
malignancies in which inactivation of
TGF-beta signaling, which is essential for
tumor suppression, is disrupted by inactivation of the ELF adaptor
protein.